Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
:KURA
Holding KURA?
Track your performance easily
KURA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.98 - $24.17
Previous CloseN/A
Volume631.17K
Average Volume (3M)1.66M
Market Cap
$558.34M
Enterprise Value$1.26B
Total Cash (Recent Filing)$67.79M
Total Debt (Recent Filing)$7.32M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Feb 20, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding77,763,750
10 Day Avg. Volume1,421,338
30 Day Avg. Volume1,658,423
Standard Deviation0.18
R-Squared0.05
Alpha-0.00233
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap2.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.41
Forecast
1Y Price Target
$28.17Price Target Upside292.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Kura Oncology News
PremiumCompany Announcements
Kura Oncology Announces Leadership Changes and Appointments
Bulls Say, Bears Say
Bulls Say
Clinical PerformanceKURA's data in fit AML patients provides evidence of ziftio's potential best-in-class profile in this segment, driving meaningful and potentially durable responses with rapid count recoveries.
Earnings And Market OpportunityThe focus remains on frontline population where Co predicts a ~$7B+ US market oppy with zifto potentially capturing up ~$3B.
Partnership And Financial StrengthKURA announced a surprise collaboration with Kyowa Kirin on menin inhibitor ziftomenib in AML, which includes a $330M upfront payment and eligibility for $1.2Bn in total potential milestones.
Bears Say
Efficacy ConcernsThe CR/CRh rates in combination with ven/aza in relapsed/refractory KMT2Ar AML are less than 20%, indicating a potential limitation in efficacy.
Financial PerformanceKura reported no revenues for 3Q24, with expenses higher than consensus estimates.
Stock PerformanceThe recent Kyowa Kirin partnership leading to lack of near-term M&A potential despite meaningful strategic capital/ expertise has driven KURA's weak stock performance.
---
Ownership Overview
1.47% Insiders
11.16% Mutual Funds
1.52% Other Institutional Investors
71.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $6.98 and its highest was $24.17 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $558.34M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Feb 20, 2025 which is in 33 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Nov 07, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.626 by -$0.004.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.64.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 77,763,750 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.626. Following the earnings report the stock price went down -0.506%.
Which hedge fund is a major shareholder of Kura Oncology?
Among the largest hedge funds holding Kura Oncology’s share is Deerfield Management Company, LP. It holds Kura Oncology’s shares valued at 106M.
---
Kura Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.17 (292.34% Upside)
$28.17 (292.34% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 70%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.66%
12-Months-Change
Fundamentals
Return on Equity
-46.28%
Trailing 12-Months
Asset Growth
1.07%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
---
KURA Company Deck
---
KURA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials for ziftomenib, financial stability, and regulatory achievements, but also noted increased expenses and some clinical challenges.Read More>---
KURA Stock 12 Month Forecast
Average Price Target
$28.17
▲(292.34% Upside)
Technical Analysis
Fate Therapeutics
―
Cue Biopharma
―
Blueprint Medicines
―
Rocket Pharmaceuticals
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering KURA
1 Year
1 Year Success Rate
17/43 ratings generated profit
1 Year Average Return
+17.92%
reiterated a buy rating 12 days ago
Copying Leah R. Cann's trades and holding each position for 1 Year would result in 39.53% of your transactions generating a profit, with an average return of +17.92% per trade.
---